ClinicalTrials.gg
RecruitingNCT06379958Updated Aug 9, 2024

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

A Phase 1 interventional study of leramistat 40mg and Itraconazole 200 mg in Pharmacokinetics, sponsored by Modern Biosciences Ltd. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Modern Biosciences Ltd · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Modern Biosciences Ltd is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Principal Inclusion Criteria:

Healthy, adult, male or female of non 18 to 55 years of age.

Principal Exclusion Criteria:

History or presence of medical or psychiatric condition or disease in the opinion of the PI or designee.

History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    Part 1: Itraconazole 200mg

    Drug: leramistat 40mg · Drug: Itraconazole 200 mg

  • Active comparator
    Part 2: Phenytoin 100mg

    Drug: leramistat 40mg · Drug: Phenytoin 100 Mg Oral Capsule

  • Active comparator
    Part 3: Simvastatin 40mg

    Drug: leramistat 40mg · Drug: Simvastatin 40mg

  • Active comparator
    Part 4: Upadacitinib 15 mg

    Drug: leramistat 40mg · Drug: Upadacitinib 15 MG

Interventions

06

What researchers measure

Primary outcomes

  1. leramistat: Area under the curve - AUC0-t

    Time frame: 8.5 Weeks

  2. leramistat: Area under the curve - AUC0-24h

    Time frame: 8.5 Weeks

  3. leramistat: Area under the curve - AUC0-inf

    Time frame: 8.5 weeks

  4. leramistat: Maximum observed concentration - Cmax

    Time frame: 8.5 weeks

  5. leramistat: Time of the maximum observed concentration - Tmax

    Time frame: 8.5 weeks

  6. leramistat:Elimination rate constant -Kel

    Time frame: 8.5 weeks

  7. leramistat: Half life - t½

    Time frame: 8.5 weeks

  8. leramistat: Plasma Clearance -CL/F

    Time frame: 8.5 weeks

  9. leramistat: Volume of distribution - Vz/F

    Time frame: 8.5 weeks

Secondary outcomes

  1. Incidence of adverse event.

    Time frame: 8.5 weeks

07

Study locations

1 of 1 sites recruiting
  • Celerion
    Belfast, United Kingdom
    Recruiting
    • Phase 1 Unit · Contact
    • Nadine Abdullah · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Sep 2024, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 23, 2024
StartActual
Apr 8, 2024
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06379958
Lead sponsor
Modern Biosciences Ltd
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Apr 8, 2024
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2024 (estimated)
Last update
Aug 9, 2024

Study contacts

Study Team
Contact
ist05@istesso.co.uk
+44 (0)207 444 0066

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Leramistat · Simvastatin · Upadacitinib

Start the discussion